Previous Article | Next Article 
Journal of Clinical Microbiology, June 2000, p. 2324-2329, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Diagnostic Potential of Puumala Virus Nucleocapsid
Protein Expressed in Drosophila melanogaster Cells
Katarina
Brus
Sjölander,1
Irina
Golovljova,2
Alexander
Plyusnin,3,4 and
Åke
Lundkvist1,3,*
Swedish Institute for Infectious Disease
Control, S-171 82 Stockholm,1 and
Microbiology and Tumor Biology Center, Karolinska Institute,
S-171 77 Stockholm,3 Sweden; Institute
of Preventive Medicine, Virus Ecology Laboratory, Tallinn EE0006,
Estonia2; and Haartman Institute,
Department of Virology, FIN-00014 University of Helsinki, Helsinki,
Finland4
Received 2 December 1999/Returned for modification 7 February
2000/Accepted 25 March 2000
 |
ABSTRACT |
Puumala virus (PUU) nucleocapsid protein (N) was expressed in
insect cells by using the Drosophila Expression System (DES; Invitrogen
BV, Groningen, The Netherlands). Stable transfectants were established
by hygromycin B selection and showed continuous expression of the
recombinant protein (DES-PUU-N) for at least 5 months. The antigenic
property of DES-PUU-N was shown to be identical to that of native PUU N
when examined with a panel of hantavirus-specific monoclonal
antibodies. Enzyme-linked immunosorbent assays (ELISAs) for detection
of human immunoglobulin M (IgM) and IgG antibodies were established by
using DES-PUU-N as antigen and were compared to assays based on native
N. The ELISAs were evaluated for patient diagnosis and
seroepidemiological purposes with panels of sera collected from
patients with hemorrhagic fever with renal syndrome (HFRS) and from
healthy blood donors. Equally high sensitivities and specificities for
detection of PUU-specific IgM in acute-phase HFRS patient sera were
obtained by the ELISA based on DES-PUU-N and the assay based on the
native antigen. For detection of PUU-specific IgG, the ELISA based on
monoclonal antibody-captured DES-PUU-N antigen showed optimal
sensitivity and specificity.
 |
INTRODUCTION |
Puumala virus (PUU), a member of the
Hantavirus genus, family Bunyaviridae, is a
causative agent of hemorrhagic fever with renal syndrome (HFRS)
(25). Hantaviruses are negative-stranded RNA viruses with a
tripartite genome; the S segment encodes a nucleocapsid protein (N),
the M segment encodes two glycoproteins, G1 and G2, and the L segment
encodes an RNA polymerase (24, 27). Hantaviruses are
transmitted to humans from rodent hosts, probably through inhalation of
aerosolized excreta. The bank vole (Clethrionomys glareolus)
is the major rodent carrier of PUU (25). HFRS caused by PUU
is generally milder than HFRS caused by Dobrava virus (DOB) or Hantaan
virus (HTN) and is rarely manifested by hemorrhage. Although the
mortality rate from PUU infections is low (<0.2%), the virus causes
significant morbidity in northern and eastern Europe; each year western
Russia, Finland, Sweden, and Norway report about 5,000, 1,000, 300, and
50 cases, respectively. Sporadic outbreaks are observed in central
Europe, and we have recently reported major outbreaks with hundreds of
cases in Bosnia and Belgium (7, 17).
The diagnosis of PUU infections requires serological confirmation.
Although reverse transcription-PCR has been successfully applied for
detection of PUU RNA in a limited number of patient samples (8,
22, 23), the test can be used only during the first week of the
disease, and even within this period, the level of viremia seems to be
close to the limit of sensitivity (23). Thus, reverse
transcription-PCR cannot be recommended as a test that can be used for
the routine diagnosis of PUU infections. The N PUU has been
demonstrated to be the major antigenic target in the early human
antibody response, and high levels of N-specific antibodies are
produced during the acute phase of the disease (5, 16, 30).
For diagnosis of acute hantavirus infections, assays that measure
immunoglobulin M (IgM) antibody levels have been shown to be the most
informative; the virus-specific IgM levels rise earlier than the IgG
antibody levels, and IgM production is clearly associated with acute
infection (1, 12, 16).
The increasing awareness of hantavirus infections in Europe has created
an urgent need for rapid and reliable diagnostic assays. As pathogenic
hantaviruses require biosafety level 3 facilities for propagation,
alternative means of production of viral antigens are preferred. We and
others have previously established hantavirus antibody-specific
enzyme-linked immunosorbent assays (ELISAs) based on total N or
truncated variants expressed in Escherichia coli (3, 5,
11, 12, 33). For the diagnosis of PUU and DOB infections, we
recently found that assays based on the total N protein expressed in
the baculovirus system had optimal performances (1, 9, 10, 12,
31).
The aim of this study was to produce recombinant PUU N antigen in the
Drosophila Expression System (DES; Invitrogen, Groningen, The
Netherlands) and to evaluate the suitability of this recombinant protein as a diagnostic antigen.
 |
MATERIALS AND METHODS |
Cloning and expression of recombinant protein.
For cloning
into the pAc5.1/V5-His vector (DES; Invitrogen) the entire open reading
frame (ORF) for the N protein (nucleotides 43 to 1341) was amplified
with primers containing KpnI and NotI restriction
sites (underlined below; Fig. 1): forward
primer, TTG GTA CCA TGA GTG ACT TGA CAG ACA TCC AA; reverse
primer, TAA TAA ACT TGC GGC CGC CAT ATC TTT AAG GGC. The
cDNA clone of the PUU Kazan strain S segment (14) was used
as a template for PCR, according to a standard protocol. The PCR
product was cloned into the pAc5.1/V5-His vector and amplified by
standard molecular biological techniques and was subsequently prepared
for transfection into Schneider (S2) cells (29).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 1.
Constitution of pAc5.1/V5-His/Kaz-S. The entire ORF for
the N protein of PUU (strain Kazan) was amplified and cloned into the
KpnI and NotI sites of the pAc5.1/V5-His vector
as described in Materials and Methods.
|
|
The correct sequence of the recombinant DNA was confirmed by cycle
sequencing performed on an FTS-320 Thermal Sequencer by using the PRISM
Ready BigDye Terminator Cycle Sequencing kit with AmpliTaq DNA
Polymerase FS (Taq-FS; Perkin-Elmer, Applied Biosystems Division,
Foster City, Calif.). The total reaction volume was 20 µl (8 µl of
PRISM premix, 3.2 pmol of sequencing primer, and 500 ng of DNA). The
sample was analyzed with an ABI377 sequencer (Perkin-Elmer, Applied
Biosystems Division).
Transient transfections of S2 cells were performed according to the
manufacturer's instructions (Invitrogen). Briefly, the purified cloned
vector (pAc5.1/V5-His/Kaz-S) was transfected by use of calcium
phosphate (Invitrogen) into 2 × 106 to 4 × 106 S2 cells/ml in six-well cell culture plates (Costar).
The cells were harvested at 48, 72, 96, 120, and 144 h after
plasmid transfection.
Cell lines for stable expression of the recombinant protein (DES-PUU-N)
were established by selection with hygromycin B according to the
manufacturer's instructions (Invitrogen). Briefly, 19 µg of
pAc5.1/V5-His/Kaz-S and 1 µg of pCoHYGRO were cotransfected with
calcium phosphate into 2 × 106 to 4 × 106 S2 cells/ml in six-well cell culture plates according
to the manufacturer's instructions (Invitrogen). After 16 to 24 h
of incubation at room temperature, the calcium phosphate was removed by
centrifugation. Two days later, 400 µg of hygromycin B per ml was
added, as determined by kill-curve titrations (the lowest concentration
of hygromycin B which resulted in total cell death after 4 days of
incubation), and resistant cells were expanded for 4 weeks. Cells were
continuously harvested every 7 days.
Production of recombinant antigen.
For production of
DES-PUU-N, transfected cells were cultured in DES Expression media
(Invitrogen) supplemented with 10% fetal calf serum, antibiotics, and
hygromycin B at room temperature. The cells were collected by
centrifugation, and proteinase inhibitors (10 mg of leupeptin per ml,
10 mg of pepstatin A per ml, and 1 mg of aprotinin per ml [Boehringer
Mannheim] and 10 mM EDTA) were added. The cell pellets were stored at
20°C until they were used. The cell pellets were dissolved in
phosphate-buffered saline (PBS) and sonicated on ice (five times for
5 s each time). To test the antigenicity of the protein, aliquots
were tested by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis in 4 to 15% polyacrylamide gels, transferred onto
nitrocellulose filters, and immunoblotted with a pool of PUU N-reactive
monoclonal antibodies (MAbs; 1C12, 4C3, 5B5, and 3G5) as described
earlier (15).
Native viral antigen.
Native PUU antigens for ELISA were
produced as described previously (15, 16). The antigen used
for IgM detection consisted of sonicated extracts of infected Vero E6
cells, and the antigen used for IgG detection consisted of infected
cells treated with a detergent-containing buffer.
Serum panels.
Patient sera, previously analyzed in the
diagnostic routine at the Swedish Institute for Infectious Disease
Control, Stockholm, Sweden, by a µ-capture IgM ELISA based on native
viral antigen, as described below, were used to evaluate the DES-PUU-N
IgM ELISA. The panel consisted of acute-phase sera from 131 serologically confirmed (PUU IgM-positive) patients, all with clinical
symptoms of PUU infection, and 114 serum samples from patients with
suspicion of HFRS but with negative serological test results for PUU
IgM. In addition, 40 serum samples from patients with other acute viral infections (varicella-zoster virus, measles virus, influenza A virus,
and cytomegalovirus) were analyzed.
For evaluation of the IgG assays, a panel of 185 serum samples from
apparently healthy individuals (blood donors) in Sweden and Latvia were used.
Buffers for ELISA.
Carbonate buffer (50 mM; pH 9.6) was used
for antibody coating in all assays. The blocking step was performed by
incubation with 3% bovine serum albumin in PBS for 1 h at 37°C.
All sera, conjugates, and the antigens used in the following steps of
the ELISAs were diluted in PBS with 0.05% Tween 20 plus 0.5% bovine serum albumin. Tetramethylbenzidine or
p-nitrophenylphosphate (pNPP) was used as a substrate, as
described by the manufacturer (Sigma). The plates were washed five
times in 0.9% NaCl with 0.05% Tween 20 between each step.
MAb detection assay.
A panel of hantavirus-specific MAbs was
used to compare the antigenic properties of the recombinant protein
with those of the corresponding native antigen. The panel contained the
PUU N MAbs 1C12, 4C3, 3G5, 2E12, 5B5, 3H9, 5F4, and 5E1 (15,
19) and the Tula virus (TUL) N MAbs 1C8, 3C11, 7A4, 6A6, and 3D3
(20). The antigenic recognition sites of the MAbs are shown
in Table 1. The plates were coated with rabbit anti-PUU diluted 1:300 (17) overnight at 4°C, after which they were blocked prior
to use. The antigens were incubated for 1 h at 37°C, followed by incubation of the MAbs at a concentration of 2 µg/ml in duplicate for
1 h at 37°C. Specific antibody binding was detected by
incubation of alkaline phosphatase-conjugated anti-mouse IgG (Jackson)
diluted 1:1,000 for 1 h at 37°C, followed by incubation of pNPP.
Optical densities were measured after 30 min at 405 nm.
FRNT.
The focus-reduction neutralization test (FRNT) was
performed as described earlier (17). An 80% reduction in
the number of foci compared to the number for the virus control was
used as the criterion for virus neutralization titers.
IgM and IgG ELISAs.
PUU IgM µ-capture ELISAs, based on
DES-PUU-N or native antigens, were performed essentially as described
previously (1, 13). Briefly, microtiter plates were coated
with goat anti-human IgM (Cappel, Organon Technica, Turnhout, Belgium),
blocked, and incubated with patient or control sera at a 1:200
dilution. Each antigen was added at optimal concentrations, as
determined by box titration, followed by the addition of PUU N-specific
peroxidase-conjugated bank vole MAb 1C12 (15) and
tetramethylbenzidine substrate. To calculate the results, all
absorbances were adjusted according to a standard control PUU-positive
serum, for which the mean optical density (OD) value for duplicate
wells was recalculated to 1.000. Background ODs for the control wells
were reduced from the ODs for the wells incubated with antigen. Cutoff
values for positive samples were set at an OD of 0.150.
PUU IgG ELISAs based on MAb-captured DES-PUU-N or native antigens were
performed essentially as described previously (1, 16).
Briefly, microtiter plates were coated with MAb 1C12 (1 µg/ml) and
were incubated overnight at 4°C. After blocking, the antigens were
incubated, followed by incubation of serum samples (diluted 1:400) in
duplicate wells in both antigen-sensitized and control wells. Goat
anti-human IgG (
-chain specific; Sigma) alkaline phosphatase
conjugate was added, followed by the addition of pNPP substrate. The
results were calculated as described above for the IgM ELISAs except
for the use of late-convalescent-phase serum from patients with PUU
infection as the standard control and the use of different cutoff
values for positive samples, which were set at an OD of 0.100.
 |
RESULTS |
Expression of DES-PUU-N.
The plasmid pAc5.1/V5-His/Kaz-S,
which contains the full-length PUU N ORF correctly inserted, as
confirmed by complete nucleotide sequencing, was transfected into S2
cells. To estimate the optimal amount of plasmid DNA required for
maximal expression levels, 1, 5, 10, 15, 20, 30, or 40 µg of
pAc5.1/V5-His/Kaz-S was transfected to equal numbers of S2 cells. A
band of the expected size (approximately 54 kDa) was detected with a
pool of PUU-specific MAbs (Fig. 2 and
data not shown). The results indicated that 20 µg of the plasmid DNA
was the optimal concentration.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 2.
DES-PUU-N (approximately 54 kDa) immunoblotted with a
pool of PUU N-reactive MAbs (MAbs 1C12, 4C3, 5B5, and 3G5) after
transient transfection of various amounts of pAc5.1/V5-His/Kaz-S to
equal numbers of S2 cells. Lane 1, 10 µg; lane 2, 20 µg; lane 3, 30 µg; lane 4, 40 µg; lane 5, negative control (S2 cells); lane 6, positive control (native PUU N antigen). Molecular masses (in
kilodaltons) are indicated to the right.
|
|
To estimate the optimal time of cell culture required for maximum
expression levels, 20 µg of pAc5.1/V5-His/Kaz-S was transfected to S2
cells, which were harvested 48, 72, 96, 120, and 144 h later. The
result indicated that maximum expression of the protein (DES-PUU-N) was
obtained at 96 h after the transfection (data not shown).
Antigenic properties of DES-PUU-N.
The hantavirus-specific
MAbs reacted with DES-PUU-N in the ELISA with a pattern identical to
that seen with native PUU antigen (Table
1). Notably, the two epitopes, N-a and
N-e, previously shown to be missing in E. coli-expressed PUU
N (4, 18, 31) were clearly recognized.
Establishment of stable transfectants.
The plasmids
pAc5.1/V5-His/Kaz-S and pCoHYGRO were cotransfected to 2 × 106 to 4 × 106 S2 cells/ml in 3 ml of
medium. After 6 weeks of selection with 400 µg of hygromycin B per
ml, cells were continuously analyzed for expression of the recombinant
protein at 1.5, 3, 4, and 5 months after the transfection (Table
2). The results indicated a continuous
expression for at least 5 months. Frozen stocks of stable
DES-PUU-N-expressing cells have been successfully thawed and cultivated
after 1 month of storage in liquid nitrogen (Table 2).
To estimate the amounts of DES-PUU-N expressed by the stable
transfectants, crude cell extracts were titrated to the end point, and
the results were compared to those for native PUU N and purified recombinant PUU N (rN-Kaz) of known concentration expressed in E. coli (C. de Carvalho Nicacio and Å. Lundkvist, unpublished data)
in IgG and IgM ELISAs (Fig. 3 and data
not shown). The results indicated that one 225-cm2 flask
(inoculated with approximately 3.4 × 107 stable
transfectants) yielded 0.6 to 1.8 mg of DES-PUU-N after 1 week of
culture, which is equal to the antigen amount required for 80 to 240 IgG ELISA plates or for examination of 1,200 to 3,600 serum samples in
duplicate. To obtain similar amounts of native PUU N, harvests from
1.25 to 5 roller bottles (800 cm2) with monolayers of Vero
E6 cells inoculated for 14 days were required, indicating an
approximately 5- to 20-fold higher efficiency for the DES system.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
IgG ELISA titration curves. Results for known
concentrations of purified rN-Kaz ( ) were compared to those for
dilution series (starting from 1:10 with twofold dilutions) of crude
extracts of DES-PUU-N ( ; stable transfectants harvested from one
225-cm2 cell culture flask and sonicated in 5 ml) and
native PUU N ( ; infected cells from five 800-cm2 roller
bottles and sonicated in 5 ml). OD, optical density at 405 nm.
|
|
Stability of DES-PUU-N.
The stability of DES-PUU-N was
evaluated by incubating aliquots of sonicated crude cell extracts at 4, 20, and 37°C for 1, 7, and 14 days, respectively. The results
revealed a significant decrease in the activity of the antigen over
time and at higher temperatures when it was used for the IgM ELISA
(Fig. 4A). In contrast, when the antigen
was analyzed by the IgG ELISA, almost no difference in activity could
be observed (Fig. 4B). The stability of the antigen was further
evaluated by repeated freezing-thawing of aliquots stored at
20°C.
The results revealed that the antigen was completely stable for up to
six cycles of freezing-thawing, irrespective of whether it was used for
the IgM or the IgG ELISA (Table 3).

View larger version (66K):
[in this window]
[in a new window]
|
FIG. 4.
DES-PUU-N from sonicated crude cell extracts examined
for stability over time and temperature. (A) IgM ELISA. (B) IgG ELISA.
OD, optical density at 450 (A) or 405 (B) nm.
|
|
Detection by PUU-specific IgM.
A panel of 131 serum specimens
from HFRS patients and from 114 serum specimens from patients with
similar clinical symptoms, all previously examined by µ-capture IgM
ELISA based on native viral antigen for routine diagnosis, were used
for evaluation of the DES-PUU-N-based IgM ELISA (test data are
summarized in Table 4). The ELISA showed
that optimal specificity and sensitivity were achieved; i.e., all sera
reacted identically compared to the reactivities of the sera by the
µ-capture ELISA based on the native antigen. Furthermore, none of 40 serum samples from patients with other acute viral infections were
reactive.
Detection by PUU IgG ELISA.
The IgG ELISA based on DES-PUU-N
was evaluated with a panel of serum specimens from healthy individuals
in Sweden and Latvia (test data are summarized in Table
5). Of 33 PUU-positive serum specimens,
as determined by neutralization assay, all were found to be IgG
positive by the MAb-antigen-capture ELISAs based on DES-PUU-N or native
antigen. All 152 serum samples negative for PUU neutralizing antibodies
and negative for PUU IgG when assayed by the ELISA with the native
antigen were also negative by the DES-PUU-N IgG ELISA.
 |
DISCUSSION |
Nephropathia epidemica (NE), the form of HFRS caused by PUU which
is commonly encountered in northern and central Europe, is a febrile
disease associated with acute renal impairment. A rapid and reliable
diagnosis is therefore of great importance for differentiation of NE
from other acute febrile illnesses in areas where PUU is endemic.
Serological assays are needed for diagnosis of hantavirus infection
since only two-thirds of PUU-infected patients (22, 23) and
approximately 40% of DOB-infected patients (21) are viral
RNA positive by current PCR tests and the isolation of hantaviruses
from HFRS patients is usually impossible. Due to the high sensitivity
combined with the ability for rapid processing of large numbers of
samples, ELISA has become the method of choice for the diagnosis of
hantavirus infections. Results are obtained within a few hours and do
not suffer from ambiguities due to subjective interpretations of
immunofluorescence assays. Although the amino-terminal region of PUU N
has been shown to constitute a major antigenic target in the human
antibody response (4, 6), our data have indicated the
presence of immunodominant regions also in the central and the
carboxy-terminal parts of the protein, indicating that use of
full-length N is essential for proper assay sensitivity (1, 13,
30).
Baculovirus-expressed PUU N antigen has, in contrast to E. coli-expressed PUU N, been found to be antigenically
indistinguishable from the native protein (4, 18, 31), and
we have to date used this antigen most successfully for diagnosis of
PUU infection in patients and seroepidemiological studies (1,
12; K. Brus Sjölander and Å. Lundkvist,
unpublished data). However, there are certain drawbacks with the
baculovirus system, especially the complicated procedure for antigen
production, including repeated titrations of the recombinant virus in
plaque assays, the need for specific and separated incubators for
handling of the infectious recombinant virus at 27°C, a sensitive
target cell line (Sf9) that requires expensive culture media, and the
fact that baculovirus kills the target cells in a few days, which makes
continuous production of the antigen impossible.
In an attempt to improve and simplify the means of production of a
high-quality recombinant antigen for use in the diagnosis of PUU
infections, we expressed PUU N in DES. On the basis of our and others'
positive experiences with the baculovirus system (1, 10, 12, 26,
28, 31, 32), we selected another insect cell system that has
several advantages: (i) the single-step transfection procedure for
immediate expression, (ii) the simple and straightforward procedure for
the establishment of stable transfectants, and (iii) the easy on-bench
handling of the target cells (room temperature, no CO2
requirements, no need for trypsinization).
The antigenic characteristics of DES-PUU-N were found to be
indistinguishable from those of native or baculovirus-expressed N when
they were analyzed with a panel of MAbs raised against PUU and TUL.
Previous data for various E. coli-expressed PUU N proteins
have revealed that epitope N-a or N-e, or both, is missing (4, 18,
31). Several assays based on E. coli-expressed N were
previously shown to suffer from low sensitivities and specificities, probably due to incorrect folding of the recombinant proteins, i.e., a
lack of epitopes important for recognition by human antibodies (1).
The need for purified antigen was efficiently circumvented by the use
of the capture format of the ELISAs. The yield of active antigen from
crude cell extracts, estimated to be 0.6 to 1.8 mg from 3.4 × 107 cells (similar to the numbers of cells in three
75-cm2 flasks), which was significantly higher than that of
native viral antigen, proved the efficiency of the system.
When the stability of the DES-PUU-N antigen was evaluated, the results
indicated that the IgM ELISA was more dependent on freshly thawed
antigen than the IgG ELISA. Incubation of antigen fractions at
different temperatures for 1, 7, and 14 days revealed a clear decrease
in IgM ELISA activity over time and with increasing temperature. In
contrast, when the same antigen fractions were examined by IgG
ELISA, the samples showed almost identical activities independent of
time and temperature, indicating that the IgG test is not as dependent
as the IgM ELISA on a totally intact antigen. A possible explanation is
that the IgM ELISA, in contrast to the IgG ELISA, to some extent
requires an aggregated antigen and that the aggregation may be lost
over time at higher temperatures. In line with this observation, our
previous trials with highly soluble truncated forms of recombinant N in
the IgM ELISA were completely unsuccessful, while the same antigen
worked well in the IgG ELISA (1). The crude recombinant
antigen preparation was, however, found to be stable against repeated
freezing-thawing, with no detectable loss of activity after six cycles.
After long-term culture, a decrease in the expression levels over time
was revealed by both IgG and IgM ELISA end-point titrations. However,
at the termination of the experiment (after 5 months of continuous
culture), significant levels of the recombinant antigen were still expressed.
The data concerning IgM assays showed that the IgM µ-capture ELISA
based on DES-PUU-N had sensitivity and specificity equal to those of
the assay based on native virus antigen. All 131 serum samples from
patients with NE and previously confirmed to have acute PUU infection
according to the routine diagnosis scored positive, while no
nonspecific reactions were seen.
In comparison to the IgG ELISA based on native antigen and the
neutralization test results, the IgG ELISA based on crude extracts of
DES-PUU-N antigen were found to be equally efficient for the detection
of PUU-specific antibodies. Native antigen is difficult to produce due
to the hazardous nature of the virus, while DES-PUU-N is easy to
produce without the need for biological containment conditions. The
higher levels of expression of DES-PUU-N compared to the low levels of
antigen obtained when native virus is cultured further points to the
advantage of this system. Another advantage of the DES-PUU-N based
system, in comparison to E. coli-expressed rN, is that no
purification of the antigen seems to be needed.
Although significant serological cross-reactivities are seen among
several of the hantaviruses, e.g., within the
PUU-Topografov-Khabarovsk-Tula-Prospect Hill hantavirus group, assays
based on PUU antigen do not efficiently detect antibodies to more
distantly related hantaviruses, such as DOB or HTN. Furthermore, our
recent results have proved the need for the homologous DOB antigen for
optimal serodiagnosis (2). Therefore, in areas where
serologically distinct hantaviruses pathogenic for humans circulate,
e.g., in the former Yugoslavia, tests based on at least two antigens
are needed for proper diagnosis of patient infections. We are working
on the establishment of high-quality serological assays based on
recombinant antigens for the diagnosis of DOB infections.
In conclusion, use of DES enabled the straightforward and efficient
production of a high-quality recombinant PUU N protein with antigenic
characteristics indistinguishable from those of the native antigen. The
specificity and sensitivity of the PUU IgM assays based on DES-PUU-N
and native N protein were equal. The IgG assay based on MAb-captured
DES-PUU-N had results identical to those of an IgG ELISA based on
native antigen and the neutralization assay when applied to a panel of
serum specimens from healthy individuals.
 |
ACKNOWLEDGMENTS |
This work was financially supported by grants from the Swedish
Medical Research Council (projects 12177 and 12642) and the Swedish
Society of Medicine and by the European Community (contract BMH4-CT97-2499). A.P. was supported by a postdoctoral fellowship from
the Karolinska Institute.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Swedish
Institute for Infectious Disease Control, Department of Virology,
Tomtebodavägen 12B, S-171 82 Stockholm, Sweden. Phone:
46-8-4572641. Fax: 46-8-314744. E-mail:
akelun{at}mbox.ki.se.
 |
REFERENCES |
| 1.
|
Brus Sjölander, K.,
F. Elgh,
H. Kallio-Kokko,
O. Vapalahti,
M. Hägglund,
V. Palmcrantz,
P. Juto,
A. Vaheri,
B. Niklasson, and Å. Lundkvist.
1997.
Evaluation of serological methods for diagnosis of Puumala hantavirus infection (nephropathia epidemica).
J. Clin. Microbiol.
35:3264-3268[Abstract].
|
| 2.
|
Brus Sjölander, K., and Å. Lundkvist.
1999.
Dobrava virus infection: serological diagnosis and cross-reactions to other hantaviruses.
J. Virol. Methods
80:137-143[CrossRef][Medline].
|
| 3.
|
Elgh, F.,
Å. Lundkvist,
O. A. Alexeyev,
H. Stenlund,
T. Avsic-Zupanc,
B. Hjelle,
H. W. Lee,
K. J. Smith,
R. Vainionpää,
D. Wiger,
G. Wadell, and P. Juto.
1997.
Serological diagnosis of hantavirus infection by enzyme-linked immunosorbent assay based on detection of immunoglobulin G and M responses to recombinant nucleocapsid protein of five viral serotypes.
J. Clin. Microbiol.
35:1122-1130[Abstract].
|
| 4.
|
Elgh, F.,
Å. Lundkvist,
O. A. Alexeyev,
G. Wadell, and P. Juto.
1996.
A major antigenic domain for the human humoral response to Puumala virus nucleocapsid protein is located at the amino-terminus.
J. Virol. Methods
59:161-172[CrossRef][Medline].
|
| 5.
|
Elgh, F.,
G. Wadell, and P. Juto.
1995.
Comparison of the kinetics of Puumala virus specific IgM and IgG antibody responses in nephropathia epidemica as measured by a recombinant antigen-based enzyme-linked immunosorbent assay and an immunofluorescence test.
J. Med. Virol.
45:146-150[Medline].
|
| 6.
|
Gött, P.,
L. Zöller,
G. Darai, and E. K. Bautz.
1997.
A major antigenic domain of hantaviruses is located on the aminoproximal site of the viral nucleocapsid protein.
Virus Genes
14:31-40[CrossRef][Medline].
|
| 7.
|
Heyman, P.,
T. Vervoort,
P. Colson,
Y. K. Chu,
T. Avsic-Zupanc, and Å. Lundkvist.
1999.
A major outbreak of hantavirus infection in Belgium in 1995 and 1996.
Epidemiol. Infect.
122:447-453[CrossRef][Medline].
|
| 8.
|
Hörling, J.,
Å. Lundkvist,
K. Persson,
M. Mullart,
T. Czagurova,
A. Dekonenko,
E. Tkachenko, and B. Niklasson.
1995.
Detection and subsequent sequencing of Puumala virus from human specimens by polymerase chain reaction.
J. Clin. Microbiol.
33:277-282[Abstract].
|
| 9.
|
Ivanov, A.,
O. Vapalahti,
H. Lankinen,
E. Tkachenko,
A. Vaheri,
B. Niklasson, and Å. Lundkvist.
1996.
Biotin-labeled antigen: a novel approach for detection of Puumala virus-specific IgM.
J. Virol. Methods
62:87-92[CrossRef][Medline].
|
| 10.
| Kallio-Kokko, H., Å. Lundkvist, A. Plyusnin, T. Avsic-Zupanc, A. Vaheri, and O. Vapalahti. Antigenic properties
and diagnostic potential of recombinant Dobrava virus nucleocapsid
protein. J. Med. Virol., in press.
|
| 11.
|
Kallio-Kokko, H.,
O. Vapalahti,
K. Hedman,
M. Brummer-Korvenkontio, and A. Vaheri.
1993.
Puumala virus antibody and immunoglobulin G avidity assays based on a recombinant nucleocapsid antigen.
J. Clin. Microbiol.
31:677-680[Abstract/Free Full Text].
|
| 12.
|
Kallio-Kokko, H.,
O. Vapalahti,
Å. Lundkvist, and A. Vaheri.
1998.
Evaluation of Puumala virus IgG and IgM enzyme immunoassays based on recombinant baculovirus-expressed nucleocapsid protein for early nephropathia epidemica diagnosis.
Clin. Diagn. Virol.
10:83-90[CrossRef][Medline].
|
| 13.
|
Lundkvist, Å.,
S. Björsten,
B. Niklasson, and N. Ahlborg.
1995.
Mapping of B-cell determinants in the nucleocapsid protein of Puumala virus; definition of epitopes specific for acute IgG recognition in humans.
Clin. Diagn. Lab. Immunol.
2:82-86[Abstract].
|
| 14.
|
Lundkvist, Å.,
Y. Cheng,
K. Brus Sjölander,
B. Niklasson,
A. Vaheri, and A. Plyusnin.
1997.
Cell culture adaptation of Puumala hantavirus changes the infectivity for its natural reservoir, Clethrionomys glareolus, and leads to accumulation of mutants with altered genomic RNA S segment.
J. Virol.
71:9515-9523[Abstract].
|
| 15.
|
Lundkvist, Å.,
A. Fatouros, and B. Niklasson.
1991.
Antigenic variation of European haemorrhagic fever with renal syndrome virus strains characterized using bank vole monoclonal antibodies.
J. Gen. Virol.
72:2097-2103[Abstract/Free Full Text].
|
| 16.
|
Lundkvist, Å.,
J. Hörling, and B. Niklasson.
1993.
The humoral response to Puumala virus infection (nephropathia epidemica) investigated by viral protein specific immunoassays.
Arch. Virol.
130:121-130[CrossRef][Medline].
|
| 17.
|
Lundkvist, Å.,
M. Hukic,
J. Hörling,
M. Gilljam,
S. Nichol, and S. Niklasson.
1997.
Puumala and Dobrava viruses cause hemorrhagic fever with renal syndrome in Bosnia-Herzegovina: evidence of highly cross-neutralizing antibody responses in early patient sera.
J. Med. Virol.
53:51-59[CrossRef][Medline].
|
| 18.
|
Lundkvist, Å.,
H. Kallio Kokko,
K. B. Sjölander,
H. Lankinen,
B. Niklasson,
A. Vaheri, and O. Vapalahti.
1996.
Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity.
Virology
216:397-406[CrossRef][Medline].
|
| 19.
|
Lundkvist, Å., and B. Niklasson.
1992.
Bank vole monoclonal antibodies against Puumala virus envelope glycoproteins: identification of epitopes involved in neutralization.
Arch. Virol.
126:93-105[CrossRef][Medline].
|
| 20.
|
Lundkvist, Å.,
O. Vapalahti,
A. Plyusnin,
K. Brus Sjölander,
B. Niklasson, and A. Vaheri.
1996.
Tula hantavirus nucleocapsid protein: characterization of antigenic determinants defined by monoclonal antibodies raised against baculovirus-expressed protein.
Virus Res.
45:29-44[CrossRef][Medline].
|
| 21.
|
Papa, A.,
A. M. Johnson,
P. C. Stockton,
M. D. Bowen,
C. F. Spiropoulou,
S. Alexiou-Daniel,
T. G. Ksiazek,
S. T. Nichol, and A. Antoniadis.
1998.
Retrospective serological and genetic study of the distribution of hantaviruses in Greece.
J. Med. Virol.
55:321-327[CrossRef][Medline].
|
| 22.
|
Plyusnin, A.,
J. Hörling,
M. Kanerva,
J. Mustonen,
Y. Cheng,
J. Partanen,
O. Vapalahti,
S. K. J. Kukkonen,
J. Niemimaa,
H. Henttonen,
B. Niklasson,
Å. Lundkvist, and A. Vaheri.
1997.
Puumala hantavirus genome in patients with nephropathia epidemica: correlation of PCR positivity with HLA haplotype and link to viral sequences in local rodents.
J. Clin. Microbiol.
35:1090-1096[Abstract].
|
| 23.
|
Plyusnin, A.,
J. Mustonen,
K. Asikainen,
A. Plyusnina,
J. Niemimaa,
H. Henttonen, and A. Vaheri.
1999.
Analysis of Puumala hantavirus genome in patients with nephropathia epidemica and rodent carriers from the sites of infection.
J. Med. Virol.
59:397-405[CrossRef][Medline].
|
| 24.
|
Plyusnin, A.,
O. Vapalahti, and A. Vaheri.
1996.
Hantaviruses: genome structure, expression and evolution.
J. Gen. Virol.
77:2677-2687[Abstract/Free Full Text].
|
| 25.
| Plyusnin, A., D. Kruger, and Å. Lundkvist.
Hantavirus infections in Europe. Adv. Virus Res., in press.
|
| 26.
|
Rossi, C. A.,
C. S. Schmaljohn,
J. M. Meegan, and J. W. LeDuc.
1990.
Diagnostic potential of a baculovirus-expressed nucleocapsid protein for hantaviruses. Arch. Virol. Suppl. 1, p. 19-28.
.
|
| 27.
|
Schmaljohn, C. S.,
S. E. Hasty,
J. M. Dalrymple,
J. W. LeDuc,
H. W. Lee,
C.-H. von Bonsdorff,
M. Brummer-Korvenkontio,
A. Vaheri,
T. F. Tsai,
H. L. Regnery,
D. Goldgaber, and P. W. Lee.
1985.
Antigenic and genetic properties of viruses linked to hemorrhagic fever with renal syndrome.
Science
227:1041-1044[Abstract/Free Full Text].
|
| 28.
|
Schmaljohn, C. S.,
K. Sugiyama,
A. L. Schmaljohn, and D. H. Bishop.
1988.
Baculovirus expression of the small genome segment of Hantaan virus and potential use of the expressed nucleocapsid protein as a diagnostic antigen.
J. Gen. Virol.
69:777-786[Abstract/Free Full Text].
|
| 29.
|
Schneider, I.
1972.
Cell lines derived from late embryonic stages of Drosophila melanogaster.
J. Embryol. Exp. Morph.
27:363-365.
|
| 30.
|
Vapalahti, O.,
H. Kallio-Kokko,
A. Närvänen,
I. Julkunen,
Å. Lundkvist,
A. Plyusnin,
H. Lehväslaiho,
M. Brummer-Korvenkontio,
A. Vaheri, and H. Lankinen.
1995.
Human B-cell epitopes of Puumala virus nucleocapsid protein, the major antigen in early serological response.
J. Med. Virol.
46:293-303[Medline].
|
| 31.
|
Vapalahti, O.,
Å. Lundkvist,
H. Kallio-Kokko,
K. Paukku,
I. Julkunen,
H. Lankinen, and A. Vaheri.
1996.
Antigenic properties and diagnostic potential of Puumala virus nucleocapsid protein expressed in insect cells.
J. Clin. Microbiol.
34:119-125[Abstract].
|
| 32.
|
Yoshimatsu, K.,
J. Arikawa,
R. Yoshida,
H. Lee,
Y. C. Yoo,
H. Kariwa,
N. Hashimoto,
M. Kikinuma,
T. Nobunaga, and I. Azuma.
1995.
Production of recombinant hantavirus nucleocapsid protein expressed in silkworm larvae and its use as a diagnostic antigen in detecting antibodies in serum from infected rats.
Lab. Anim. Sci.
45:641-646[Medline].
|
| 33.
|
Zöller, L.,
S. Yang,
P. Gött,
E. K. F. Bautz, and G. Darai.
1993.
A novel µ-capture EIA based on recombinant proteins for sensitive and specific diagnosis of hemorrhagic fever with renal syndrome.
J. Clin. Microbiol.
31:1194-1199[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, June 2000, p. 2324-2329, Vol. 38, No. 6
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Meisel, H., Wolbert, A., Razanskiene, A., Marg, A., Kazaks, A., Sasnauskas, K., Pauli, G., Ulrich, R., Kruger, D. H.
(2006). Development of Novel Immunoglobulin G (IgG), IgA, and IgM Enzyme Immunoassays Based on Recombinant Puumala and Dobrava Hantavirus Nucleocapsid Proteins. CVI
13: 1349-1357
[Abstract]
[Full Text]
-
Billecocq, A., Coudrier, D., Boue, F., Combes, B., Zeller, H., Artois, M., Bouloy, M.
(2003). Expression of the Nucleoprotein of the Puumala Virus from the Recombinant Semliki Forest Virus Replicon: Characterization and Use as a Potential Diagnostic Tool. CVI
10: 658-663
[Abstract]
[Full Text]
-
Klingstrom, J., Plyusnin, A., Vaheri, A., Lundkvist, A.
(2002). Wild-Type Puumala Hantavirus Infection Induces Cytokines, C-Reactive Protein, Creatinine, and Nitric Oxide in Cynomolgus Macaques. J. Virol.
76: 444-449
[Abstract]
[Full Text]
-
Hujakka, H., Koistinen, V., Eerikainen, P., Kuronen, I., Mononen, I., Parviainen, M., Lundkvist, A., Vaheri, A., Narvanen, A., Vapalahti, O.
(2001). New Immunochromatographic Rapid Test for Diagnosis of Acute Puumala Virus Infection. J. Clin. Microbiol.
39: 2146-2150
[Abstract]
[Full Text]